[The genetic factors of non-response to anti-vascular endothelial growth factor therapy].
Zhonghua Yan Ke Za Zhi
; 54(11): 873-878, 2018 Nov 11.
Article
in Zh
| MEDLINE
| ID: mdl-30440160
ABSTRACT
The response to anti-vascular endothelial growth factor (VEGF) treatment is variable. It is generally measured in terms of changes in correlated functional and/or anatomical outcomes, and patients are then classified as optimal response, poor response and non-response. The precise cause of non-response remains undetermined. A variety of factors could account for poor or non-response to anti-VEGF therapy, such as age, baseline vision, disease course, lesion characteristics and genomic polymorphism. At the present time, many studies on the genetic factors of non-response or poor response to anti-VEGF treatment mainly focus on VEGF genes (VEGF-A, VEGFR-2), complement factor H (CFH), age-related maculopathy susceptibility 2 (LOC387715/ARMS2), high temperature factor A-1 (HTRA1), interleukin-related gene (IL-8 rs4073) and so forth. It is still worthy of further investigations that how to assess genetic reasons for non-response or poor response, so that we can provide individualized treatment sequences and predict the response to anti-VEGF therapy. (Chin J Ophthalmol, 2018, 54873-878).
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Drug Resistance
/
Angiogenesis Inhibitors
/
Vascular Endothelial Growth Factor A
Type of study:
Prognostic_studies
Limits:
Humans
Language:
Zh
Journal:
Zhonghua Yan Ke Za Zhi
Year:
2018
Document type:
Article
Affiliation country:
China
Publication country:
CHINA
/
CN
/
REPUBLIC OF CHINA